BioCryst to Present at Upcoming Investor Conferences
May 26 2021 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company will present at the Jefferies Virtual Healthcare
Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET and the JMP
Securities Life Sciences Conference on Thursday, June 17, 2021 at
1:30 p.m. ET. Both are being conducted as virtual conferences.
Links to a live audio webcast and replay of
these presentations may be accessed in the Investors section of
BioCryst’s website at http://www.biocryst.com.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States, European
Union, Japan and the United Kingdom for the prevention of HAE
attacks in adults and pediatric patients 12 years and older.
BioCryst has several ongoing development programs including
BCX9930, an oral Factor D inhibitor for the treatment of
complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva, and
galidesivir, a potential treatment for Marburg virus disease and
Yellow Fever. RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, has
received regulatory approval in the U.S., Canada, Australia, Japan,
Taiwan and Korea. Post-marketing commitments for RAPIVAB are
ongoing. For more information, please visit the company’s website
at www.biocryst.com.
BCRXW
Investors:John Bluth+1 919 859
7910jbluth@biocryst.com
Media:Catherine Collier
Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024